StockNews.AI
SEPN
StockNews.AI
181 days

Kirby McInerney LLP Announces Investigation Against Septerna, Inc. (SEPN) on Behalf of Investors

1. Septerna faces investigation for potential federal securities law violations. 2. The company halted its Phase 1 clinical trial of SEP-786 due to safety concerns. 3. Septerna's stock fell approximately 46% following the trial discontinuation announcement. 4. Two severe liver-related incidents triggered the termination of the clinical trial. 5. Kirby McInerney LLP is gathering claims from affected Septerna investors.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The halted clinical trial and investigation raise concerns about SEPN's growth prospects. Similar past incidents have led to significant stock declines.

How important is it?

The investigation and trial termination are highly significant to SEPN's market value and investor confidence. Such legal matters can substantially impact stock performance.

Why Short Term?

Immediate negative sentiment from the halted trial and investigations will likely affect SEPN quickly. Market reactions to such news generally manifest in the short term.

Related Companies

SEPNKMLP
NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Septerna, Inc. (“Septerna” or the “Company”) (NASDAQ:SEPN). The investigation concerns whether Septerna and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On February 18, 2025, Septerna announced its decision to discontinue the Phase 1 single- and multiple-ascending dose (SAD/MAD) clinical trial of SEP-786, an oral small molecule PTH1R agonist for treating hypoparathyroidism, in healthy volunteers. Septerna stated that this decision was based on the observation of two unexpected severe (Grade 3) cases of elevated unconjugated bilirubin in the MAD portion of the trial, both occurring without corresponding increases in ALT, AST, or GGT liver enzyme levels. On this news, the price of Septerna shares declined by $6.09 per share, or approximately 46%, from $12.96 per share on February 14, 2025, to close at $6.87 on February 18, 2025. If you purchased or otherwise acquired Septerna securities, have information, or would like to learn more about this investigation, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out the form below to discuss your rights or interests with respect to these matters without any cost to you. [CONTACT US] Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. ContactsKirby McInerney LLPThomas W. Elrod, Esq.212-699-1180https://www.kmllp.cominvestigations@kmllp.com

Related News